India, June 30 -- Shilpa Medicare announced that its wholly owned subsidiary, Shilpa Biologicals, has entered into a co development and supply agreement with Orion Corporation for intravenous(IV) nivolumab biosimilar referencing one of the world's most widely used cancer immunotherapies ' bringing two companies together to widen patient access across Europe.Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients across cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients ' and to help health systems stretch every euro of their oncology budgets...